Gabriel Hinojosa, PharmD, BCOP, looks beyond frontline regimens in multiple myeloma, and discusses treatment options, adverse events, and complexities in sequencing therapies.
This is a video synopsis/summary of an Insights involving Gabriel Hinojosa, PharmD, BCOP.
Hinojosa explored treatment options beyond DRd (daratumumab, lenalidomide, dexamethasone), VRd (bortezomib, lenalidomide, dexamethasone), and KRd (carfilzomib, lenalidomide, dexamethasone) for patients with multiple myeloma, emphasizing diverse regimens based on patient lifestyles and responses. He discussed new drug approvals, including bispecific T-cell engagers and chimeric antigen receptor (CAR) T-cell therapy, providing breakthroughs for patients with limited options. Sequencing therapies remain a challenge, with limited data guiding choices. Beyond the fourth line, the introduction of therapies targeting BCMA and GPRC5D along with CAR T-cell therapy, adds complexity to treatment decisions. Adverse events in later lines include cytokine release syndrome and immune effector cell-associated neurotoxicity, requiring vigilant monitoring for potentially life-threatening complications. The evolving landscape underscores the need for more data and individualized approaches to optimize outcomes in multiple myeloma.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.